Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Deborah A. Scollard"'
Publikováno v:
Molecular Pharmaceutics. 14:492-501
Heterodimerization of EGFR with HER2 coexpressed in breast cancer (BC) promotes tumor growth, and increased EGFR expression is associated with trastuzumab resistance. Our aim was to construct 64Cu-labeled bispecific radioimmunoconjugates (bsRIC) comp
Autor:
Bing Wu, Douglass Vines, Amer Shammas, Reza Vali, Trevor Do, Trevor D. McKee, Libo Zhang, Deborah A. Scollard, Milan Ganguly, Travis Besanger, Sylvain Baruchel, Teesha Komal, Natasha Alexander
Publikováno v:
Contrast Media & Molecular Imaging, Vol 2017 (2017)
Contrast Media & Molecular Imaging
Contrast Media & Molecular Imaging
Peptide-receptor imaging and therapy with radiolabeled somatostatin analogs such as 68Ga-DOTA-TATE and 177Lu-DOTA-TATE have become an effective treatment option for SSTR-positive neuroendocrine tumors. The purpose of this study was to evaluate the co
Publikováno v:
Applied Radiation and Isotopes. 95:135-142
We previously reported that 111In-labeled pertuzumab imaged trastuzumab (Herceptin)-mediated changes in HER2 expression preclinically in breast cancer tumors. To advance 111In-labeled pertuzumab to a Phase I/II clinical trial, a kit was designed for
Autor:
Raymond M. Reilly, Curtis B. Caldwell, Harriette J. Kahn, Deborah A. Scollard, Claire M. B. Holloway, Lisa E. Ehrlich
Publikováno v:
Nuclear Medicine and Biology. 40:630-637
Introduction Our aim was to conduct a Phase I clinical trial to determine the feasibility of intraoperative detection of tumor margins in HER2 positive breast carcinoma using a hand-held γ-probe following administration of 111 In-DTPA-trastuzumab Fa
Publikováno v:
Breast Cancer Research and Treatment. 138:709-718
Epidermal growth factor receptors (EGFR) form heterodimers with HER2 in breast cancer, and increased EGFR expression has been found in HER2-positive tumors resistant to trastuzumab (Herceptin). Our objective was to synthesize bispecific radioimmunoco
Autor:
Bart Cornelissen, Kristin McLarty, Susan J. Done, Zhongli Cai, Danny L. Costantini, Deborah A. Scollard, Raymond M. Reilly
UNLABELLED: Pertuzumab is a HER2 dimerization inhibitor that binds to an epitope unique from that of trastuzumab. Our objective was to determine whether SPECT with (111)In-diethylenetriaminepentaacetic acid-pertuzumab ((111)In-DTPA-pertuzumab) could
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fb288790aa315510268f79c6fe2aacb
https://doi.org/10.2967/jnumed.109.062224
https://doi.org/10.2967/jnumed.109.062224
Introduction Our objective was to evaluate the tumor and normal tissue distribution and nuclear importation properties of [ 111 In]-mouse IgG (mIgG) conjugated to tat peptides (GRKKRRQRRRPPQGYG) in athymic mice with subcutaneous BT-474 human breast c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b077e4632e6b5b3090f2e37416390cfd
https://ora.ox.ac.uk/objects/uuid:5d76366e-f8e3-4d4a-9de6-f22afbc568f8
https://ora.ox.ac.uk/objects/uuid:5d76366e-f8e3-4d4a-9de6-f22afbc568f8
Publikováno v:
Nuclear Medicine and Biology. 38:129-136
Introduction The human epidermal growth factor receptor-2 (HER2) gene is amplified in 25% of invasive breast cancers, and receptor overexpression has been noted in up to 60% of early stages of the disease [ductal carcinoma in situ (DCIS)]. Preclinica
Autor:
Danny L. Costantini, Zhuo Chen, Zhongli Cai, Kristy E. Bailey, Raymond M. Reilly, Katherine A. Vallis, Deborah A. Scollard
Publikováno v:
Journal of Nuclear Medicine. 48:1562-1570
UNLABELLED: (111)In-DTPA-human epidermal growth factor ((111)In-DTPA-hEGF [DTPA is diethylenetriaminepentaacetic acid]) is an Auger electron-emitting radiopharmaceutical that targets EGF receptor (EGFR)-positive cancer. The purpose of this study was
Autor:
Michael Wiese, Kerstin Breitbach, Werner Klinkhammer, Micheline Piquette-Miller, Deborah A. Scollard, Raymond M. Reilly, Veronika Jekerle
Publikováno v:
International Journal of Cancer. 119:414-422
Overexpression of the multidrug resistance proteins P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) results in treatment failure of many malignancies including ovarian cancer. Dual inhibition of Pgp and BCRP may restore the sensitivi